0001474064-12-000073.txt : 20121221 0001474064-12-000073.hdr.sgml : 20121221 20121221160249 ACCESSION NUMBER: 0001474064-12-000073 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121221 FILED AS OF DATE: 20121221 DATE AS OF CHANGE: 20121221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nader Francois CENTRAL INDEX KEY: 0001365343 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 121281484 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2012-12-21 0000890465 NPS PHARMACEUTICALS INC NPSP 0001365343 Nader Francois 550 HILLS DRIVE BEDMINSTER NJ 07921 1 1 0 0 President, CEO and Director Stock Options 3.34 2012-12-21 4 A 0 108000 0 A 2020-02-19 Common Stock 108000 108000 D On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On December 21, 2012, the performance criteria for 108,000 of these options was satisfied when the FDA unanimously voted to approve the NDA for GATTEX for the treatment of SBS. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. /s/ Francois Nader, by Edward Stratemeier as attorney-in-fact 2012-12-21